AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12788879
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (all doses)
Trial: 1351796
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of loratadine
Trial: 26804606
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation program administered by volunteers for eight weeks, three times each week
Trial: 24890747
Drug: 12-hour magnesium
RxNorm normalized name: magnesium chloride 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour magnesium sulfate therapy
Trial: 24890747
Drug: 24-hour magnesium
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour magnesium sulfate therapy
Trial: 15919798
Drug: hOKT3gamma1(Ala-Ala) monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hOKT3gamma1(Ala-Ala) monoclonal antibody
Trial: 12843392
Drug: N-methyl-D-aspartate-receptor blocker
RxNorm normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-methyl-D-aspartate-receptor blocker
Trial: 12843392
Drug: Left index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left index finger (no drug)
Trial: 10655977
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Cu-glycine chelate (CuGC)
Trial: 10655977
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg Cu-glycine chelate (CuGC)
Trial: 31443886
Drug: Baltimore City
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baltimore City Drug Treatment Court (BCDTC)
Trial: 30153453
Drug: Increasing-distance interval
RxNorm normalized name: Cistanche tinctoria stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing-distance interval training (100–200–300–400–500 m), twice a week for six weeks
Trial: 30153453
Drug: Decreasing-distance interval
RxNorm normalized name: Cistanche tinctoria stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing-distance interval training (500–400–300–200–100 m), twice a week for six weeks
Trial: 28229646
Drug: PT +
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT + NT (Physical Training + Nutritional Therapy)
Trial: 24680961
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release tablet Sirdalud(®)
Trial: 22985205
Drug: Fluoxetine-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine-only
Trial: 20030470
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg with tapentadol IR 80 mg
Trial: 20030470
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg with tapentadol IR 80 mg
Trial: 20030470
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 325 mg with tapentadol IR 80 mg
Trial: 20030470
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 80 mg alone
Trial: 15949725
Drug: BQ-123 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (10 nmol/min) + L-NMMA (2 micromol/min)
Trial: 15949725
Drug: BQ-123 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (50 nmol/min) + L-NMMA (4 micromol/min)
Trial: 9728850
Drug: Desflurane at
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane at 1 L/min
Trial: 9728850
Drug: Isoflurane at
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane at 1 L/min
Trial: 9728850
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion with desflurane
Trial: 9728850
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion with isoflurane
Trial: 2914739
Drug: Preventive antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive antiarrhythmic treatment
Trial: 1112170
Drug: Thiordazine (THI)
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiordazine (THI) at single daily doses not exceeding 375 mg/day for 6 months
Trial: 1112170
Drug: Pimozide (PIM)
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide (PIM) at single oral doses not exceeding 16 mg/day
Trial: 1112170
Drug: Both drug
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drug groups (THI and PIM)
Trial: 31492912
Drug: PCA (proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA (proton pump inhibitors, clarithromycin, and amoxicillin)
Trial: 20965780
Drug: Pramipexole (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.125 to 0.75 mg once daily)
Trial: 16804427
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV; FluMist)
Trial: 11101476
Drug: High-meat diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-meat diet (600 g/d)
Trial: 8833212
Drug: Cyclical clodronate
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical clodronate therapy (200 mg IV infusion every 3 weeks)
Trial: 1317089
Drug: Modified soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified soft jelly capsule containing nonoxynol-9 (DF-486)
Trial: 2859931
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg qid (mean dose 340 mg/day)
Trial: 24825416
Drug: LY1 dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY1 dosing algorithm
Trial: 24825416
Drug: LY2 dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2 dosing algorithm
Trial: 24825416
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (GL) dosing algorithm
Trial: 22301439
Drug: CD4(+) T-cell-guided
RxNorm normalized name: Autologous CD4+CD25hiFoxP3+regulatory T cells
DrugBank: Autologous CD4+CD25hiFoxP3+regulatory T cells (DB18655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4(+) T-cell-guided therapy interruption (TI)
Trial: 22301439
Drug: therapy continuation
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: therapy continuation
Trial: 11994612
Drug: Telephone interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone interviews with health care providers regarding breast implant concerns
Trial: 10201101
Drug: Differential observing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differential observing response procedure; no specific dosage or duration mentioned.
Trial: 10201101
Drug: Baseline condition;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline condition; no specific dosage or duration mentioned.
Trial: 218717
Drug: Thymosin 60
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin 60 mg/m2 (T60)
Trial: 218717
Drug: Thymosin 20
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin 20 mg/m2 (T20)
Trial: 27650432
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (CBT) including psychoeducation, breathing training, and cognitive restructuring over a 6-month period
Trial: 24415784
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg daily for 24 weeks
Trial: 23094055
Drug: VS411 (didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS411 (didanosine 200 mg/HC 900 mg once-daily)
Trial: 17255270
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (DDCT)
Trial: 12431240
Drug: Standard CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CHOP (-like) chemotherapy
Trial: 12431240
Drug: Standard local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard local practice (SLP) chemotherapy
Trial: 12431240
Drug: Elderly patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly patients receiving SLP chemotherapy
Trial: 3312824
Drug: Phosphocreatine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphocreatine (8 to 10 mmol/L) in a blood cardioplegic solution
Trial: 27085828
Drug: Neoadjuvant TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant TKI therapy prior to CN (Group 2)
Trial: 27085828
Drug: Neoadjuvant TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant TKI therapy (Group 2)
Trial: 22672586
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg q.d. added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Trial: 22672586
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Trial: 20493644
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus assessment (TAU+)
Trial: 15341662
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus (saffron) 30 mg/day (TDS)
Trial: 15341662
Drug: Imipramine 100
RxNorm normalized name: trimipramine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 100 mg/day (TDS)
Trial: 10733632
Drug: Oral-PUVA
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-PUVA
Trial: 25260393
Drug: Fu Zheng
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu Zheng decoction combined with antibiotics
Trial: 25260393
Drug: Antibiotic only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic only treatment
Trial: 19360898
Drug: LY450139 (gamma-secretase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (gamma-secretase inhibitor) 100mg
Trial: 19360898
Drug: LY450139 (gamma-secretase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (gamma-secretase inhibitor) 140mg
Trial: 19360898
Drug: LY450139 (gamma-secretase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (gamma-secretase inhibitor) 280mg
Trial: 14758296
Drug: Electrical twitch-obtaining
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical twitch-obtaining intramuscular stimulation (ETOIMS)
Trial: 11527248
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (20 mg/2 mL, or 1 ampoule; Fujisawa, Osaka, Japan) four times daily for 1 week
Trial: 11527248
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL of saline) four times daily for 1 week
Trial: 8420685
Drug: Carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 300 mg/m2 plus Cyclophosphamide 600 mg/m2
Trial: 8420685
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 plus Cyclophosphamide 600 mg/m2
Trial: 26718415
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (0.06 g ∙ kg(‐1) ∙ meal(‐1))
Trial: 15728889
Drug: Tefibazumab 2
RxNorm normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tefibazumab 2 mg/kg
Trial: 15728889
Drug: Tefibazumab 5
RxNorm normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tefibazumab 5 mg/kg
Trial: 15728889
Drug: Tefibazumab 10
RxNorm normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tefibazumab 10 mg/kg
Trial: 15728889
Drug: Tefibazumab 20
RxNorm normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tefibazumab 20 mg/kg
Trial: 12853233
Drug: Arotinolol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol 10 mg per day
Trial: 12853233
Drug: Arotinolol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol 20 mg per day
Trial: 12853233
Drug: Arotinolol 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol 30 mg per day
Trial: 12853233
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg per day
Trial: 12853233
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg per day
Trial: 12853233
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg per day
Trial: 10491227
Drug: Oral 1,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 1,25(OH)2D3 (1.5 microg/m2 BSA)
Trial: 10491227
Drug: Intravenous 1,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1,25(OH)2D3 (1.5 microg/m2 BSA)
Trial: 10491227
Drug: Sr absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sr absorption without 1,25(OH)2D3 (test A)
Trial: 10491227
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of Sr and oral 1,25(OH)2D3 (test B)
Trial: 10491227
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of Sr and iv 1,25(OH)2D3 (test C)
Trial: 8699600
Drug: Unilateral thyroarytenoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral thyroarytenoid muscle injections of 15 units of botulinum toxin
Trial: 8699600
Drug: Bilateral thyroarytenoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral thyroarytenoid muscle injections of 2.5 units of botulinum toxin on each side
Trial: 1664833
Drug: Oral temafloxacin
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral temafloxacin 600 mg twice daily (n = 49)
Trial: 1664833
Drug: Intravenous cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefotaxime 2 g thrice daily (n = 51)
Trial: 7039882
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment (intense immunosuppression followed by long-term maintenance on azathioprine)
Trial: 7039882
Drug: Cells taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cells taken from patients before treatment
Trial: 31693519
Drug: Preventative multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventative multimodal analgesia (PMA) including 1000 mg of acetaminophen, 300-900 mg of gabapentin, and 200-400 mg of celecoxib 1 hour before surgery
Trial: 31693519
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of morphine-equivalent dose (MED) preoperatively
Trial: 29946148
Drug: Metformin add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin add-on to continuous subcutaneous insulin infusion (Met + CSII)
Trial: 26787402
Drug: Apple intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple intake (increase of 53 g/d)
Trial: 26787402
Drug: Apple intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple intake of 5-100 g/d
Trial: 26787402
Drug: Apple intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple intake of >100 g/d (an apple a day)
Trial: 26787402
Drug: Apple intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple intake <5 g/d (control group)
Trial: 24610902
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management without intervention and antithrombotic therapy (control group).
Trial: 22583697
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg + metformin
Trial: 22583697
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg + metformin
Trial: 22583697
Drug: Alogliptin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (12.5 or 25 mg) + metformin
Trial: 17270058
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone 8 mg
Trial: 17270058
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone 16 mg
Trial: 17270058
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone 32 mg
Trial: 17270058
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone 64 mg
Trial: 17270058
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone (all doses)
Trial: 15475600
Drug: Sodium-lactate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-lactate infusion (LC) during exercise
Trial: 15475600
Drug: Control (Con)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (Con) with isotonic, isovolumetric saline infusion during exercise
Trial: 8585710
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention to instill hope; duration: 4 weeks; specific details on dosage not available.
Trial: 15954973
Drug: Cimetidine 4
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 4 mg kg(‐1) preoperatively
Trial: 15954973
Drug: Cimetidine 4
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 4 mg kg(‐1) postoperatively
Trial: 12964500
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day zinc supplementation
Trial: 1929105
Drug: Daily corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily corticosteroid therapy (group A) for an additional year
Trial: 1929105
Drug: Alternate-day corticosteroid
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day corticosteroid therapy (group B) for an additional year
Trial: 1929105
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from daily to alternate-day corticosteroid therapy after one year (for group A)
Trial: 1578306
Drug: Alternate-day corticosteroid
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day corticosteroid therapy
Trial: 7059094
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion after acid infusion
Trial: 7059094
Drug: Placebo-antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-antacid
Trial: 30682680
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with lorazepam
Trial: 26626539
Drug: Bobath neurodevelopmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath neurodevelopmental treatment (NDT) (n = 22)
Trial: 25146692
Drug: DTG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG 50 mg q24h for 5 days followed by DTG 50 mg and EFV 600 mg q24h for 14 days
Trial: 25146692
Drug: DTG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg q12h for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days
Trial: 22614936
Drug: PM (physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM (physician management) with weekly buprenorphine dispensing
Trial: 22614936
Drug: PM+DOT/CBT (physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM+DOT/CBT (physician management and directly observed, thrice-weekly buprenorphine with cognitive-behavioral therapy)
Trial: 19066301
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/d for 3 months)
Trial: 17968836
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs (adamantanes and neuraminidase inhibitors)
Trial: 17968836
Drug: Nonpharmacologic interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic interventions (e.g., handwashing, contact isolation)
Trial: 16036028
Drug: b‐adrenergic receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b‐adrenergic receptor antagonists (b‐blockers)
Trial: 11575415
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection on median nerve stimulation (group 1)